Outcome measures for clinical trials in fragile X syndrome

Journal of Developmental and Behavioral Pediatrics

Volumn 34, Issue 7, 2013, Pages 508-522

  Berry Kravis, Elizabeth ^a   Hessl, David ^b,c   Abbeduto, Leonard ^b,c   Reiss, Allan L ^d   Beckel Mitchener, Andrea ^f   Urv, Tiina K ^e  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); COGNITION; EDUCATION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FRAGILE X SYNDROME; HUMAN; LANGUAGE; LANGUAGE TEST; LEARNING; MEMORY; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; STANDARD; TREATMENT OUTCOME;

CHILD; CLINICAL TRIALS AS TOPIC; COGNITION; EDUCATION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FRAGILE X SYNDROME; HUMANS; LANGUAGE; LANGUAGE TESTS; LEARNING; MEMORY; NEUROPSYCHOLOGICAL TESTS; TREATMENT OUTCOME;

EID: 84884693472     PISSN: 0196206X     EISSN: 15367312     Source Type: Journal    
DOI: 10.1097/DBP.0b013e31829d1f20     Document Type: Article

References (124)

1. Hagerman PJ. The fragile X prevalence paradox. J Med Genet. 2008;45:498-499
2. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, et al. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11: 324-329
3. Grossman AW, Aldridge GM, Weiler IJ, et al. Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. J Neurosci. 2006;26:7151-7155
4. Bassell GJ, Warren ST. Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron. 2008;60:201-214
5. Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247-261
6. Bhakar AL, Dölen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci. 2012;35:417-443
7. Hagerman RJ, Berry-Kravis E, Ono MY, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123:378-390
8. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome-present and future. Ment Retard Dev Disabil Res Rev. 2004;10:42-48
9. Berry-Kravis E, Sumis A, Hervey C, et al. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome. Int J Peds. 2012;2012:843016. Available at: Http://www. hindawi.com/journals/ijped/2012/ 843016/cta/. Accessed July 29, 2013
10. Hagerman RJ, Jackson AW, Levitas A, et al. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet. 1986;23:241-262
11. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988;30:377-392
12. Strom CM, Brusca RM, Pizzi WJ. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin) for the treatment of fragile X syndrome. Am J Med Genet. 1992;44:676-682
13. Hagerman RJ, Miller LJ, McGrath-Clarke J, et al. Influence of stimulants on electrodermal studies in fragile X syndrome. Microsc Res Tech. 2002;57:68-73
14. Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial. J Child Adolesc Psychopharmacol. 2006;16:525-540
15. Torrioli MG, Vernacotola S, Peruzzi L, et al. A double-blind, parallel, multicenter comparison of L-Acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008;146:803-812
16. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29:293-302
17. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46:266-271
18. Fung LK, Quintin E, Haas BW, et al. Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome. Curr Opin Neurol. 2012;25:112-124
19. Kesler SR, Lightbody AA, Reiss AL. Cholinergic dysfunction in fragile X syndrome and potential intervention: A preliminary 1H MRS study. Am J Med Genet. 2009;149A:403-407
20. Erickson CA, Mullett JE, McDougle CJ. Open-label memantine in fragile X syndrome. J Autism Dev Disord. 2009;39:1629-1635
21. Torrioli M, Vernacotola S, Setini C, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A. 2010;152A:1420-1427
22. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010;10:91
23. Erickson CA, Stigler KA, Wink LK, et al. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacol (Berl). 2011;216:85-90
24. Erickson CA, Weng N, Weiler IJ, et al. Open-label riluzole in fragile X syndrome. Brain Res. 2011;1380:264-270
25. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2012;3:64ra1
26. Hall SS, Lightbody AA, McCarthy BE, et al. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012;37:509-518
27. Berry-Kravis E, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Trans Med. 2012;4:152ra127
28. Erickson CA. Prospective open-label trial of acamprosate in youth with fragile X syndrome: A pilot study including biomarker assays. Paper presented at: International Fragile X Syndrome Meeting; July 25, 2012; Miami, F.L.
29. Berry-Kravis E, Knox A, Hervey C.Targeted treatments for fragile X syndrome. J Neurodev Disord. 2011;3:193-210
30. Hall SS, Hammond JL, Hirt M, et al. A "learning platform" approach to outcome measurement in fragile X syndrome: A preliminary psychometric study. J Intellect Disabil Res. 2012;56: 947-960
31. Abbeduto L, Brady N, Kover ST. Language development and fragile X syndrome: Profiles, syndrome-specificity, and withinsyndrome differences. Ment Retard Dev Disabil Res Rev. 2007; 13:36-46
32. Price JR, Roberts JE, Hennon EA, et al. Syntactic complexity during conversation of boys with fragile X syndrome and Down syndrome. J Speech Lang Hear Res. 2008;51:3-15
33. Abbeduto L, Murphy MM, Richmond EK, et al. Collaboration in referential communication: Comparison of youth with Down syndrome or fragile X syndrome. Am J Ment Retard. 2006;111: 170-183
34. Abbeduto L, Murphy MM, Kover ST, et al. Signaling noncomprehension of language: A comparison of fragile X syndrome and Down syndrome. Am J Ment Retard. 2008;113:214-230
35. Estigarribia B, Martin GE, Roberts JE, et al. Narrative skill in boys with fragile X syndrome with and without autism spectrum disorder. Appl Psycholinguist. 2011;32:359-388
36. Roberts J, Martin GE, Moskowitz L, et al. Discourse skills of boys with fragile X syndrome in comparison to boys with Down syndrome. J Speech Lang Hear Res. 2007;50:475-492
37. Belser RC, Sudhalter V. Conversational characteristics of children with fragile X syndrome: Repetitive speech. Am J Ment Retard. 2001;106:28-38
38. Sudhalter V, Cohen IL, Silverman W, et al. Conversational analyses of males with fragile X, Down syndrome, and autism: Comparison of the emergence of deviant language. Am J Ment Retard. 1990; 94:431-444
39. Roberts JE, Hennon EA, Price JR, et al. Expressive language during conversational speech in boys with fragile X syndrome. Am J Ment Retard. 2007;112:1-17
40. Budimirovic DB, Bukelis I, Cox C, et al. Autism spectrum disorder in Fragile X syndrome: Differential contribution of adaptive socialization and social withdrawal. Am J Med Genet A. 2006;140: 1814-1826
41. Kover ST, Abbeduto L. Expressive language in male adolescents with fragile X syndrome with and without comorbid autism. J Intellect Disabil Res. 2010;54:246-265
42. Lewis P, Abbeduto L, Murphy MM, et al. Cognitive, language, and social-cognitive skills of individuals with fragile X syndrome with and without autism. J Intellect Disabil Res. 2006;50:532-545
43. McDuffie A, Kover ST, Abbeduto L, et al. Profiles of receptive and expressive language in males with comorbid fragile X syndrome and autism. Am J Intellect Dev Disabil. 2012;117:18-32
44. Philofsky A., Hepburn SL, Hayes A, et al. Linguistic and cognitive functioning and autism symptoms in young children with Fragile X syndrome. Am J Ment Retard. 2004;109:208-218
45. Abbeduto L, Kover ST, McDuffie A. Studying the language development of children with intellectual disabilities. In Hoff E, ed. Handbook of Child Language Research Methods. West Sussex, United Kingdom: Wiley-Blackwell; 2012:330-346
46. Heilmann JJ, Miller JF, Nockerts A. Using language sample databases. Lang Speech, Hearing Serv Schools. 2010;41:84-95
47. Estigarribia B, Martin GE, Roberts JE. Cognitive, environmental, and linguistic predictors of syntax in fragile X syndrome and Down syndrome. Speech Lang Hear Res. 2012;55:1600-1612
48. Finestack LH, Abbeduto L. Expressive language profiles of verbally expressive adolescents and young adults with Down syndrome or fragile X syndrome. J Speech Lang Hear Res. 2012;53:1334-1348
49. Finestack LH, Palmer M, Abbeduto L. Macrostructural narrative language of adolescents and young adults with Down syndrome or fragile X syndrome. Am J Speech Lang Pathol. 2012;21:29-46
50. Finestack LH, Sterling A, Abbeduto L. Discriminating Down syndrome and fragile X syndrome based on language ability. J Child Lang. 2013;40:244-265
51. Abbeduto L, Benson G, Short K, et al. Effects of sampling context on the expressive language of children and adolescents with mental retardation. Ment Retard. 1995;33:279-288
52. Reber AS. Implicit Learning and Tacit Knowledge: An Essay on the Cognitive Unconscious. London, United Kingdom: Oxford University Press; 1993
53. Siegert RJ, Taylor KD, Weatherall M, et al. Is implicit sequence learning impaired in Parkinson's disease? A meta-Analysis. Neuropsychology. 2006:20:490-495
54. Baddeley AD. Working Memory. Oxford, England: Oxford University Press; 1986
55. Baddeley AD. Working memory and language: An overview. J Commun Disord. 2003;36:189-208
56. Jarrold C, Baddeley AD. Short-Term memory for verbal and visuospatial information in Down's syndrome. Cogn Neuropsychiatry. 1997;2:101-122
57. D'Esposito M, Aguirre GK, Zarahn E, et al. Functional MRI studies of spatial and nonspatial working memory. Cog Brain Res. 1998; 7:1-13
58. Walter H, Bretschneider V, Gron G, et al. Evidence for quantitative domain dominance for verbal and spatial working memory in frontal and parietal cortex. Cortex. 2003;39:897-911
59. Dykens EM, Hodapp RM, Leckman JF. Strengths and weaknesses in the intellectual functioning of males with fragile X syndrome. Am J Ment Defic. 1987;92:234-236
60. Ornstein PA, Schaaf JM, Hooper SR, et al. Memory skills of boys with fragile X syndrome. Am J Ment Retard. 2008;113:453-465
61. Acheson DJ, MacDonald MC. Verbal working memory and language production: Common approaches to the serial ordering of verbal information. Psychol Bull. 2009;135:50-68
62. Cowan N. Attention and Memory: An Integrated Framework. Oxford, England: Oxford University Press; 1995
63. Baker S, Hooper S, Skinner M, et al. Working memory subsystems and task complexity in young boys with fragile X syndrome. J Intellect Disabil Res. 2011;55:19-29
64. Cornish KM, Kogan CS, Li L, et al. Lifespan changes in working memory in fragile X premutation males. Brain Cogn. 2009;69: 551-558
65. Munir F, Cornish KM, Wilding J. A neuropsychological profile of attention deficits in young males with fragile X syndrome. Neuropsychologia. 2000;38:1261-1270
66. Cornish KF, Munir F, Wilding J. [A neuropsychological and behavioural profile of attention deficits in fragile X syndrome]. Rev Neurol. 2001;33:S24-S29
67. Lanfranchi SO, Jerman E, Dal Pont A, et al. Executive function in adolescents with Down syndrome. J Intellect Disabil Res. 2012; 54:308-319
68. Woodcock RW, Nancy M, Kevin SM. Woodcock-Johnson III Tests of Cognitive Abilities Examiner's Manual. Itasca, IL: Riverside; 2001
69. Woodcock RR, Kevin SM, Fredrick AS. Woodcock-Johnson III Normative Update Technical Manual. Itasca, IL: Riverside; 2007
70. Kessels RPC, van Zandvoort MJE, Postma A, et al. The corsi blocktapping task: Standardization and normative data. Appl Neuropsychol. 2000;7:252-258
71. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, TX: Pearson; 1998
72. Berry-Kravis E, Lara R, Kim O-K, et al. Characterization of potential outcome measures for future clinical trials in fragile X syndrome. J Autism Dev Disord. 2008;38:1751-1757
73. Welsh MC, Pennington BF. Assessing frontal lobe functioning in children: Views from developmental psychology. Dev Neuropsychol. 1988;4:199-230
74. Pennington BF. Using genetics to dissect cognition. Am J Hum Genet. 1997;60:13-16
75. Wilding JK, Cornish K, Munir F. Further delineation of the executive deficit in males with fragile-X syndrome. Neuropsychologia. 2002;40:1343-1349
76. Scerif GK, Cornish K, Wilding J, et al. Delineation of early attentional control difficulties in fragile X syndrome: Focus on neurocomputational changes. Neuropsychologia. 2007;45:1889-1898
77. Hooper SR, Hatton D, Sideris J, et al. Executive functions in young males fragile X syndrome in comparison to mental age-matched with controls: Baseline findings from a longitudinal study. Neuropsychology. 2008;22:36-47
78. Kwon H, Menon V, Eliez S, et al. Functional neuroanatomy of visuospatial working memory in fragile X syndrome: Relation to behavioral and molecular measures. Am J Psychiatry. 2001;158: 1040-1051
79. Tamm L, Menon V, Johnston CK, et al. fMRI study of cognitive interference processing in females with fragile X syndrome. J Cogn Neurosci. 2002;14:160-171
80. Gioia G, Isquith PK, Guy SC, et al. Behavior rating inventory of executive function. Child Neuropsychol. 2000;6:235-238
81. Cornish K, Burack JA, Rahman A, et al. Theory of mind deficits in children with fragile X syndrome. J Intellect Disabil Res. 2005;49: 372-378
82. Garner C, Callias M, Turk J. Executive function and theory of mind performance of boys with fragile-X syndrome. J Intellect Disabil Res. 1999;43:466-474
83. Mazzocco MM, Pennington BF, Hagerman RJ. Social cognition skills among females with fragile X. J Autism Dev Disord. 1994;24: 473-485
84. Constantino JN, Gruber CP. The Social Responsiveness Scale Manual. California, CA: Western Psychological Services; 2005
85. US Department of Health and Human Services. Patient-reported outcome measures: Use in medical product development to support labeling claims. 2006
86. Aman M, Singh N, Stewart A, et al. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485-491
87. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002; 347:314-321
88. Zarcone JR, Hellings JA, Crandall K, et al. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard. 2001;106:525-538
89. Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003;42:1443-1450
90. McDougle CJ, Scahill L, McCracken JT, et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am. 2000;9:201-224
91. Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42:1377-1392
92. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40:168-179
93. Conners' Rating Scales-Revised Technical Manual. North Tonawanda, NY: Multi Health Systems; 2000
94. Esbensen AJ, Rojahn J, Aman MG, et al. Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. J Autism Dev Disord. 2003;33:617-629
95. Cordeiro L, Ballinger E, Hagerman RJ, et al. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. J Neurodev Disord. 2011;3:57-67
96. Riddle MA, Ginsburg GS, Walkup JT, et al. The pediatric anxiety rating scale (PARS): Development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41:1061-1069
97. Russo-Ponsaran N, Yesensky J, Hessl D, et al. Feasibility, reproducibility, and clinical validity of the Pediatric Anxiety Rating Scale-Revised for fragile X syndrome. Am J Intellect Dev Disabil. 2013. In press
98. Scahill L, McDougle CJ, Williams SK, et al. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45:1114-1123
99. Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol. 2006;9:209- 213
100. Bodfish JW, Symons FJ, Parker DE, et al. Varieties of repetitive behavior in autism: Comparisons to mental retardation. J Autism Dev Disord. 2000;30:237-243
101. Lam KS, Aman MG. The Repetitive Behavior Scale-Revised: Independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37:855-866
102. Brock M, Hatton D. Distinguishing features of autism in boys with fragile X syndrome. J Intellect Disabil Res. 2010;54: 894-905
103. Sparrow SS, Cicchetti DV, Balla DA. Vineland Adaptive Behavior Scales. 2nd ed. Minneapolis, MN: Pearson Assessments; 2005
104. Seltzer MM, Abbeduto L, Greenberg JS, et al. Biomarkers in the study of families of individuals with developmental disabilities. Int Rev Res Ment Retard. 2009;37:213-249
105. Westmark C, Westmark P, O'Riordan K, et al. Reversal of fragile X phenotypes by manipulation of AßPP/Aß levels in Fmr1 KO mice. PLOS One. 2011;6:e26549
106. Gross C, Nakamoto M, Yao X, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci. 2010;30:10624-10638
107. Hoeffer CA, Sanchez E, Hagerman RJ, et al. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 2012;11:332-341
108. Hessl D, Cordeiro L, Yuhas J, et al. Prepulse inhibition in fragile X syndrome: Feasibility, reliability, and implications for treatment. Am J Med Genet. 2008;153B:545-553
109. de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008;31:127-132
110. Heilman KJ, Harden E, Berry-Kravis E, et al. Autonomic regulation in fragile X syndrome. Dev Psychobiol. 2011;53:785-795
111. Hall SS, Lightbody AA, Huffman LC, et al. Physiological correlates of social avoidance behavior in children and adolescents with fragile X syndrome. J Am Acad Child Adolesc Psychiatry. 2009;48: 320-329
112. Farzin F, Scaggs F, Hervey C, et al. Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome. J Autism Dev Disord. 2011;41:1515-1522
113. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: A twenty-year perspective. Annu Rev Pathol. 2012;7: 219-245
114. Hazlett HC, Poe MD, Lightbody AA, et al. Teasing apart the heterogeneity of autism: Same behavior, different brains in toddlers with fragile X syndrome and autism. J Neurodev Disord. 2009;1:81-90
115. Hoeft F, Lightbody AA, Hazlett HC, et al. Morphometric spatial patterns differentiating boys with fragile X syndrome, typically developing boys, and developmentally delayed boys aged 1 to 3 years. Arch Gen Psychiatry. 2008;65:1087-1097
116. Hoeft F, Walter E, Lightbody AA, et al. Neuroanatomical differences in toddler boys with fragile X syndrome and idiopathic autism. Arch Gen Psychiatry. 2011;68:295-305
117. Haas BW, Barnea-Goraly N, Lightbody AA, et al. Early white-matter abnormalities of the ventral frontostriatal pathway in fragile X syndrome. Dev Med Child Neurol. 2009;51:593-599
118. Watson C, Hoeft F, Garrett AS, et al. Aberrant brain activation during gaze processing in boys with fragile X syndrome. Arch Gen Psychiatry. 2008;65:1315-1323
119. Hallahan BP, Craig MC, Toal F, et al. In vivo brain anatomy of adult males with fragile X syndrome: An MRI study. Neuroimage. 2011; 54:16-24
120. Wilson LB, Tregellas JR, Hagerman RJ, et al. A voxel-based morphometry comparison of regional gray matter between fragile X syndrome and autism. Psychiatry Res. 2009;174:138-145
121. Lee AD, Loew AD, Lu A, et al. 3D pattern of brain abnormalities in fragile X syndrome visualized using tensor-based morphometry. Neuroimage. 2007;34:924-938
122. Hoeft F, Carter JC, Lightbody AA, et al. Region-specific alterations in brain development in one- to three-year-old boys with fragile X syndrome. Proc Natl Acad Sci U S A. 2010;107:9335-9339
123. Bray S, Hirt M, Jo B, et al. Aberrant frontal lobe maturation in adolescents with fragile X syndrome is related to delayed cognitive maturation. Biol Psychiatry. 2011;70:852-858
124. Bruno J, Shelly EW, Quintin E-M, et al. Aberrant basal ganglia metabolism in fragile X syndrome: A magnetic resonance spectroscopy study. J Dev Behav Pediatr. 2013 [In press].